1. Protein Tyrosine Kinase/RTK
  2. Btk

Btk

Bruton's tyrosine kinase (BTK) also known as tyrosine-protein kinase BTK is an enzyme that in humans is encoded by the BTK gene. BTK is a kinase that plays a crucial role in B-cell development. Its exact mechanism of action remains unknown, but it plays a crucial role in B cell maturation as well as mast cell activation through the high-affinity IgE receptor. Btk contains a PH domain that binds phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 binding induces Btk to phosphorylate phospholipase C, which in turn hydrolyzes PIP2, a phosphatidylinositol, into two second messengers, inositol triphosphate (IP3) and diacylglycerol (DAG), which then go on to modulate the activity of downstream proteins during B-cell signalling.

Btk Related Products (26):

Cat. No. Product Name Effect Purity
  • HY-10997
    PCI-32765 Inhibitor
    PCI-32765 is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM.
  • HY-17600
    Acalabrutinib Inhibitor
    Acalabrutinib is a novel, potent, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM in a human whole-blood CD69 B cell activation assay.
  • HY-18012
    AVL-292 Inhibitor
    AVL-292 is a potent inhibitor of Btk kinase activity (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s) in biochemical assays.
  • HY-80002
    BMX-IN-1 Inhibitor
    BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.
  • HY-15427
    GDC-0834 Inhibitor
    GDC-0834 is a potent and selective BTK inhibitor. GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and rat, respectively.
  • HY-101474
    BGB-3111 Inhibitor
    BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor.
  • HY-101215
    Evobrutinib Inhibitor
    Evobrutinib is an inhibitor of Bruton's tyrosin kinase (Btk) inhibitor extracted from patent US20140162983 example 0174.
  • HY-15427B
    GDC-0834 S-enantiomer
    GDC-0834 (S-enantiomer) is the S-enantiomer of GDC-0834. GDC-0834 is a potent and selective BTK inhibitor.
  • HY-11999
    CGI-1746 Inhibitor
    CGI-1746 is a potent and highly selective inhibitor of the Btk with IC50 of 1.9 nM.
  • HY-18951
    ONO-4059 analog Inhibitor
    The product is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor with an IC50 in the sub-nM range.
  • HY-19834
    GDC-0853 Inhibitor
    GDC-0853 is a potent and orally BTK inhibitor.
  • HY-18010
    PCI 29732 Inhibitor
    PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
  • HY-15771
    ONO-4059 Inhibitor
    ONO-4059 is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM.
  • HY-18009
    LFM-A13 Inhibitor
    LFM-A13 is a potent and selective inhibitor of Btk with IC50 of 17.2 uM; also inhibits PLK3 with IC50 of 7.2 uM.
  • HY-18018
    RN486 Inhibitor
    RN486 is a selective Btk inhibitor with an IC50 Value of 4.0 nM.
  • HY-80003
    QL47 Inhibitor
    QL47 is a potent, selective and irreversible BTK kinase inhibitor with IC50 of 7 nM.
  • HY-15427A
    GDC-0834 Racemate
    GDC-0834 Racemate is the racemate form of GDC-0834, which is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively.
  • HY-10997A
    PCI-32765 Racemate Inhibitor
    PCI-32765 Racemate is the racemate of PCI-32765. PCI-32765 is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM.
  • HY-15771A
    ONO-4059 hydrochloride Inhibitor
    ONO-4059 is a selective and novel inhibitor of BTK with IC50 2.2 nm, ONO-4059 binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.
  • HY-13943
    CNX-774 Inhibitor
    CNX-774 is a potent, selective, and orally available small molecule inhibitor of Btk (IC50< 1 nM) that forms a ligand-directed covalent bond with Cys-481, a non-conserved amino acid within the active site of the enzyme.